Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a

If future trials go well - now it has passed the first, Phase I, testing hurdle - it could become the longest-acting form of HIV prevention available. Currently, people can take daily pills or sometimes have injections every eight weeks,